Last reviewed · How we verify
Intravenous immunoglobulins
Intravenous immunoglobulins is a Small molecule drug developed by Centre Hospitalier Universitaire de Besancon. It is currently FDA-approved. Also known as: CLAIRYG, Gamunex 10%, Nanogam, Tegeline®.
At a glance
| Generic name | Intravenous immunoglobulins |
|---|---|
| Also known as | CLAIRYG, Gamunex 10%, Nanogam, Tegeline®, Clayrig®, |
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) (PHASE1)
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (PHASE1, PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous immunoglobulins CI brief — competitive landscape report
- Intravenous immunoglobulins updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Besancon portfolio CI
Frequently asked questions about Intravenous immunoglobulins
What is Intravenous immunoglobulins?
Intravenous immunoglobulins is a Small molecule drug developed by Centre Hospitalier Universitaire de Besancon.
Who makes Intravenous immunoglobulins?
Intravenous immunoglobulins is developed and marketed by Centre Hospitalier Universitaire de Besancon (see full Centre Hospitalier Universitaire de Besancon pipeline at /company/centre-hospitalier-universitaire-de-besancon).
Is Intravenous immunoglobulins also known as anything else?
Intravenous immunoglobulins is also known as CLAIRYG, Gamunex 10%, Nanogam, Tegeline®, Clayrig®,.
What development phase is Intravenous immunoglobulins in?
Intravenous immunoglobulins is FDA-approved (marketed).
Related
- Manufacturer: Centre Hospitalier Universitaire de Besancon — full pipeline
- Also known as: CLAIRYG, Gamunex 10%, Nanogam, Tegeline®, Clayrig®,
- Compare: Intravenous immunoglobulins vs similar drugs
- Pricing: Intravenous immunoglobulins cost, discount & access